Plain-English translation of NCT06565845 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing three different ways to treat granulomatous lobular mastitis, a long-lasting inflammatory condition of the breast that can be painful and affect how the breast looks. Researchers want to compare surgery alone, therapy alone, and a combination of both surgery and medication to see which approach works best for patients and causes the least distress.
Granulomatous lobular mastitis is difficult to treat and often comes back even after surgery, and it can cause real physical and emotional pain for patients. This study exists because no one has ever directly compared these three treatment methods in the same group of patients, so doctors don't yet know which approach is most effective or which patients prefer.
You likely qualify if…
You likely don't qualify if…
You will be assigned to one of three groups: surgery only, medication only (triple anti-tuberculosis drugs), or surgery followed by medication. Depending on which group you join, you may have a surgical procedure and/or take medications for a period of time. Throughout the study, researchers will evaluate how well the treatment works, monitor you for side effects, and ask about your satisfaction with the treatment and how it affects your quality of life.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Sponsor
First Affiliated Hospital of Harbin Medical University
Enrollment target
~350 participants
Started
August 2024
Primary completion
September 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
15 Years – 65 Years
Sex
Female only
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yi Zhou
First Affiliated Hospital of Harbin Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.